scispace - formally typeset
B

B E Souberbielle

Researcher at Pfizer

Publications -  28
Citations -  819

B E Souberbielle is an academic researcher from Pfizer. The author has contributed to research in topics: Immune system & Cytokine. The author has an hindex of 15, co-authored 26 publications receiving 790 citations. Previous affiliations of B E Souberbielle include University of St Andrews & St George's Hospital.

Papers
More filters
Journal ArticleDOI

Protein transduction: an alternative to genetic intervention?

TL;DR: This review describes the three most commonly used protein transduction vehicles; the antennapedia peptide, the herpes simplex virus VP22 protein and HIV TATprotein transduction domain.
Journal Article

Expression of a variant of cd28 on a subpopulation of human nk cells : implications for b7-mediated stimulation of nk cells

TL;DR: It is shown that human peripheral blood NK cells express the CD28 costimulatory receptor, with its detection totally dependent on the mAb used, and that B7.1 enhances the NK-mediated lysis of NK-sensitive but not ofNK-resistant tumor cells and that this increased lysis is dependent on CD28-B7 interactions as shown by the ability of Abs to block this lysis.
Journal ArticleDOI

Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury

TL;DR: In this paper, the authors compare two types of drug-induced liver injury (DILI): intrinsic/predictable or an idiosyncratic type, and compare the two forms of DILI in their manifestation and diagnosis.
Journal ArticleDOI

The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).

TL;DR: These doses of TLR7 stimulation results in a pharmacologic response at levels commensurate with predicted antiviral efficacy, but these doses are associated with SAEs, raising concerns about the therapeutic window of this class of compounds for the treatment of HCV infection.
Journal ArticleDOI

Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model

TL;DR: A novel drug is described, intended as a “single-shot ” therapy, which expresses three short hairpin RNAs (shRNAs) that simultaneously target multiple conserved regions of the HCV genome as confirmed in vitro by knockdown of an HCV replicon system.